quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:04·770d
SECFiling
Science 37 Holdings Inc. logo

SEC Form EFFECT filed by Science 37 Holdings Inc.

SNCE· Science 37 Holdings Inc.
Technology
Original source

Companies

  • SNCE
    Science 37 Holdings Inc.
    Technology

Recent analyst ratings

  • Nov 1UpdateLake Street$15.00
  • Nov 1UpdateRobert W. Baird$15.00
  • Nov 1UpdateWilliam Blair-
  • Nov 1UpdateBaird$15.00
  • Oct 22UpdateCowen & Co.$14.00

Related

  • PR197d
    Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
  • PR231d
    Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
  • PR380d
    Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial
  • PR464d
    Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation
  • PR518d
    Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial
  • PR625d
    Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
  • PR644d
    Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
  • PR665d
    Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022